- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
February 25th, 2009
Financings Roundup Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round.
"We were gratified to find a very receptive audience at a very difficult time," said Robert Bratzler, executive chairman of the Watertown, Mass.-based firm. He called the Series B "our first substantial round," following $2.5 million in seed funding in May 2008 from Polaris Venture Partners and Flagship Ventures.
Both of those investors returned for the Series B, joined by NanoDimension, a VC firm that focuses on nanotechnologies, and individual investor Timothy A. Springer, a professor of pathology at Harvard Medical School and previous founder of LeukoSite Inc., which was acquired by Millennium Pharmaceuticals Inc. in 1999.
|Related News Press|
News and information
Kalam: versatility personified August 1st, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015
Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Self-assembling, biomimetic membranes may aid water filtration August 1st, 2015